Clinical trials: Duloxetine
Fibromyalgia, Hyperbaric Oxygen
Hyperbaric Oxygen Compared to Pharmaceutical Therapies for Fibromyalgia Syndrome
The investigators have previously studied the efficacy of hyperbaric oxygen therapy (HBOT) as a treatment for Fibromyalgia syndrome (FMS) in a prospective, active control, crossover clinical trial.
- Trial name
- FMSRCT (NCT03325959)
- Testing
- Hyperbaric oxygen therapy (HBOT) treatment, Cymbalta / Lyrica treatment, Crossover Hyperbaric oxygen therapy
- Where
- Israel
- Volunteers
- 76 people
- Sponsor
- Assaf-Harofeh Medical Center
Alcohol Use Disorder
Behavioral Effects of Drugs: Inpatient (36) (Alcohol, Duloxetine, and Methylphenidate)
This study will evaluate the behavioral effects of alcohol during maintenance on placebo, duloxetine, methylphenidate and duloxetine combined with methylphenidate using sophisticated human laboratory methods.
- Trial name
- BED[IN]:36 (NCT03575403)
- Testing
- Alcohol, Duloxetine (60 MG), Methylphenidate
- Where
- United States
- Volunteers
- 19 people, healthy volunteers welcome
- Sponsor
- Craig Rush
Depressive Disorder, Treatment-Resistant
A Study to Evaluate the Efficacy, Safety, and Tolerability of Intranasal Esketamine Plus an Oral Antidepressant in Elderly Participants With Treatment-resistant Depression
The purpose of this study is to evaluate the efficacy and safety of switching elderly participants with treatment-resistant depression (TRD) from a prior antidepressant treatment (to which they have not responded) to either…
- Trial name
- TRANSFORM-3 (NCT02422186)
- Testing
- Esketamine, Duloxetine (Oral Antidepressant), Escitalopram (Oral Antidepressant)
- Where
- 69 sites in United States, Belgium and 10 more
- Volunteers
- 139 people
- Sponsor
- Janssen Research & Development, LLC
Major Depressive Disorder
Efficacy and Safety Study of SPD489 in Combination With an Antidepressant in the Treatment of Adults With Major Depressive Disorder
This study will examine SPD489 in subjects aged 18-65 with major depressive disorder (MDD) who are taking certain types of antidepressants but continue to have residual depression symptoms.
- Trial name
- NCT01436162
- Testing
- Antidepressant + SPD489 (Lisdexamfetamine dimesylate )
- Where
- 101 sites in United States, Belgium and 9 more
- Volunteers
- 1,105 people
- Sponsor
- Shire
Neuropathic Pain
Determination of the Antidepressant Duloxetine in Plasma to Improve the Knowledge of the Analgesic Action of Antidepressants on Chronic Neuropathic Pain
The primary purpose of this protocol is to evaluate the lowest plasma concentration (ie before the daily taking dose of duloxetine) in patients relieved of at least 30% of their neuropathic pain with duloxetine treatment.
- Trial name
- DULOPLASM (NCT02846701)
- Testing
- duloxetine
- Volunteers
- 8 people
- Sponsor
- University Hospital, Strasbourg, France
Chronic Phantom Limb Pain
Open Label Study of Duloxetine for the Treatment of Phantom Limb Pain
This is a study to assess the possible benefit of duloxetine in the treatment of chronic phantom limb pain.
- Trial name
- NCT00425230
- Testing
- Duloxetine
- Where
- United States
- Volunteers
- 15 people, healthy volunteers welcome
- Sponsor
- Baylor College of Medicine
Fibromyalgia (FM), tDCS
Home-based Transcranial Direct Current Stimulation (tDCS) Compared to Duloxetine: Non-inferiority Clinical Trial (FIBROSTIM)
Fibromyalgia is characterized by widespread pain, fatigue, non-restorative sleep, and psychocognitive alterations, compromising quality of life and leading to absenteeism and early retirement.
- Conditions
- Fibromyalgia (FM), tDCS, Duloxetine, BDNF
- Trial name
- FIBROSTIM (NCT07203339)
- Testing
- Duloxetine (60 mg) once daily, Home-based transcranial direct current stimulation, Duloxetine 60 mg
- Where
- Brazil
- Volunteers
- 610 people
- Sponsor
- Hospital de Clinicas de Porto Alegre
Pain
Pain Prevention and Treatment Through the Enhancement of the Anti-nociceptive Component of Pain Modulation Profiles
To utilize the plasticity of the central pain pathways in order to (i) shift individuals with a pro-nociceptive pain modulation profile towards an anti-nociceptive one, and (ii) assess its relevance in minimizing pain-derived…
- Trial name
- NCT02020122
- Testing
- Duloxetine, Pregabalin
- Where
- Israel
- Volunteers
- 5 people, healthy volunteers welcome
- Sponsor
- Rambam Health Care Campus
Diabetic Neuropathy, Painful
Tolerability of Switching to Duloxetine for the Management of Diabetic Nerve Pain
This study is to compare the tolerability of different methods for switching from another medication to duloxetine for the management of diabetic nerve pain.
- Trial name
- NCT00266643
- Testing
- duloxetine hydrochloride
- Where
- 20 sites in United States, Puerto Rico
- Volunteers
- 205 people
- Sponsor
- Eli Lilly and Company
Modified Radical Mastectomy, Postoperative Analgesia
Duloxetine for Postoperative Analgesia After Modified Radical Mastectomy
The aim of this study is to evaluate the role of duloxetine in controlling pain after radical mastectomy.
- Trial name
- NCT05442268
- Testing
- Acetaminophen group, Duloxetine group
- Where
- Egypt
- Volunteers
- 40 people
- Sponsor
- Tanta University
Obsessive Compulsive Disorder
Duloxetine for the Treatment of Obsessive Compulsive Disorder (OCD)
The purpose of this study is to assess the efficacy of Duloxetine in the treatment of obsessive compulsive disorder.
- Trial name
- FIJ-MC-1003 (NCT00464698)
- Testing
- Duloxetine
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Massachusetts General Hospital
Major Depressive Disorder
Aripiprazole Augmentation Versus Switching to Different Class of Antidepressants in Major Depressive Disorder
The objective of this study is to compare the efficacy and safety of aripiprazole as adjunctive therapy versus switching to different class of antidepressants for treating major depressive disorder partially or minimally…
- Trial name
- NCT01488266
- Testing
- Aripiprazole, switching to different class of antidepressant
- Where
- 2 sites in South Korea, Taiwan
- Volunteers
- 90 people
- Sponsor
- Korea University
Major Depressive Disorder, Soft Tissue Discomfort Syndrome
Functional Change and Efficacy of Duloxetine in Patients With Co-Morbid Depression & Soft Tissue Discomfort Syndrome
The objective of this study is to determine the time course of duloxetine efficacy on the symptoms of Major Depressive Disorder (MDD)and on the symptoms of Soft Tissue Discomfort Syndrome(STDS) via use of 24-hour Actigraph™…
- Conditions
- Major Depressive Disorder, Soft Tissue Discomfort Syndrome, Pain
- Trial name
- NCT01035073
- Testing
- Duloxetine
- Where
- United States
- Volunteers
- 22 people
- Sponsor
- University of Pennsylvania
Depressive Disorder, Treatment-Resistant
A Study of Intranasal Esketamine Plus an Oral Antidepressant for Relapse Prevention in Adult Participants With Treatment-resistant Depression
The purpose of this study is to assess the efficacy of intranasal esketamine plus an oral antidepressant compared with an oral antidepressant (active comparator) plus intranasal placebo in delaying relapse of depressive symptoms…
- Trial name
- SUSTAIN-1 (NCT02493868)
- Testing
- Esketamine, Duloxetine (Oral Antidepressant), Escitalopram (Oral antidepressant)
- Where
- 155 sites in United States, Belgium and 13 more
- Volunteers
- 719 people
- Sponsor
- Janssen Research & Development, LLC
Cryptogenic Sensory Polyneuropathy
Patient Assisted Intervention for Neuropathy: Comparison of Treatment in Real Life Situations
The purpose of this large comparative effectiveness study led by Richard J. Barohn, MD, of the University of Kansas Medical Center, is to learn about the safety and effectiveness of nortriptyline, duloxetine, pregabalin and…
- Trial name
- PAIN-CONTRoLS (NCT02260388)
- Testing
- Nortriptyline, Duloxetine, Pregabalin
- Where
- 46 sites in United States, Canada
- Volunteers
- 402 people
- Sponsor
- University of Kansas Medical Center
Depressive Disorder, Treatment-Resistant
A Study of Esketamine Nasal Spray Plus a New Standard-of-care Oral Antidepressant or Placebo Nasal Spray Plus a New Standard-of-care Oral Antidepressant in Adult and Elderly Participants With Treatment-resistant Depression
The purpose of this study is to evaluate the efficacy of treating participants with treatment-resistant depression (TRD) who have failed at least 2 (and no more than 6) prior antidepressant (AD) treatments in the current moderate…
- Trial name
- NCT03852160
- Testing
- Esketamine 28 mg, Esketamine 56 mg, Esketamine 84 mg
- Sponsor
- Janssen-Cilag International NV
Neuropathic Pain
'Fix the Dysfunction' Concept for Mechanism-based Pharmacological Treatment of Neuropathic Pain by Drug
Introduction Treatment of neuropathic pain has been a goal of numerous research projects for the last half century, with overall disappointing results.
- Trial name
- 0381-16 (NCT03276689)
- Testing
- Duloxetine, Pregabaline
- Where
- Israel
- Volunteers
- 300 people, healthy volunteers welcome
- Sponsor
- Rambam Health Care Campus
Major Depressive Disorder
Study of Placebo Without Deception Versus Standard Antidepressant for Major Depressive Disorder
In recent years, there has been growing evidence that antidepressants are only marginally effective compared to placebo for mild to moderate depression.
- Trial name
- NCT01650740
- Testing
- Duloxetine, Study visits only
- Where
- Canada
- Volunteers
- 1 people
- Sponsor
- Sunnybrook Health Sciences Centre
Acute Pain
Duloxetine for Acute Post-mastectomy Pain
The objective of this study is to evaluate the analgesic effect of oral dulexitine tablet (administered 2 h before surgery) as well as the ideal dose for acute postmastectomy pain.
- Trial name
- NCT03468348
- Testing
- Duloxetine
- Where
- Egypt
- Volunteers
- 88 people
- Sponsor
- Assiut University
Depression, Pain
Subject Information and Consent Form F1J-US-HMCB Duloxetine Once-Daily Dosing Versus Placebo in Patients With Major Depression and Pain
The purposes of this study are to determine whether an investigational drug can help patients suffering from major depression with pain symptoms, and gather data on the safety of the investigational drug including any side…
- Trial name
- NCT00036335
- Testing
- Duloxetine Hydrochloride
- Where
- 25 sites in United States
- Volunteers
- 286 people
- Sponsor
- Eli Lilly and Company